{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:49:58Z","timestamp":1791838198097,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We sought to evaluate the clinical implication of LAE based on left atrial anterior\u2013posterior (LA AP) dimension or LA volume index (LAVI) in Korean patients with atrial fibrillation (AF). We enrolled 8159 AF patients from the CODE-AF registry. The primary outcome was rate of stroke or systemic embolism (SSE). The prevalence of mild, moderate, and severe LAE by LA AP dimension was 30.6%, 18.5%, and 21.4%, and by LAVI (available in 5808 patients) was 15.7%, 12.5% and 37.8%, respectively. Compared with no or mild LAE, patients with significant LAE (moderate to severe LAE, n\u2009=\u20093258, 39.9%) were associated with a higher rate of SSE (2.5% vs. 1.4%, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Multivariable analysis suggested presence of significant LAE by LA AP dimension was associated with a higher risk of SSE in the overall population (HR 1.57, 95% CI: 1.14\u20132.17, <jats:italic>P<\/jats:italic>\u2009=\u20090.005) and in patients using anticoagulants (n\u2009=\u20095836, HR 1.79, 95% CI: 1.23\u20132.63, <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Patients with significant LAE by LAVI were also at higher risk of SSE (HR 1.58, 95% CI: 1.09\u20132.29, <jats:italic>P<\/jats:italic>\u2009=\u20090.017). In conclusion, significant LAE by LA dimension or LAVI was present in 39.9% and 50.2% of AF patients, respectively, and was associated with a higher rate of SSE.<\/jats:p>","DOI":"10.1038\/s41598-021-03266-z","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T11:03:37Z","timestamp":1639134217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical impact of left atrial enlargement in Korean patients with atrial fibrillation"],"prefix":"10.1038","volume":"11","author":[{"given":"Min Soo","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung-Seob","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Jin","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Ryoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbeom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Woon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemin","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Sun","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyoung","family":"Joung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"3266_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am. J. Med. 113, 359\u2013364 (2002).","journal-title":"Am. J. Med."},{"key":"3266_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacep.2019.12.013","volume":"6","author":"JK Sajeev","year":"2020","unstructured":"Sajeev, J. K., Kalman, J. M., Dewey, H., Cooke, J. C. & Teh, A. W. The atrium and embolic stroke: Myopathy not atrial fibrillation as the requisite determinant?. JACC Clin. Electrophysiol. 6, 251\u2013261 (2020).","journal-title":"JACC Clin. Electrophysiol."},{"key":"3266_CR3","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2005.03.020","volume":"45","author":"B Olshansky","year":"2005","unstructured":"Olshansky, B. et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. J. Am. Coll. Cardiol. 45, 2026\u20132033 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3266_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0002-9149(99)80100-3","volume":"76","author":"GC Flaker","year":"1995","unstructured":"Flaker, G. C., Fletcher, K. A., Rothbart, R. M., Halperin, J. L. & Hart, R. G. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke prevention in atrial fibrillation (SPAF) investigators. Am. J. Cardiol. 76, 355\u2013358 (1995).","journal-title":"Am. J. Cardiol."},{"key":"3266_CR5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.114.03975","volume":"64","author":"M Bombelli","year":"2014","unstructured":"Bombelli, M. et al. Prognostic significance of left atrial enlargement in a general population: Results of the PAMELA study. Hypertension (Dallas, Tex) 64, 1205\u20131211 (2014).","journal-title":"Hypertension (Dallas, Tex)"},{"key":"3266_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/europace\/eux013","volume":"20","author":"A Njoku","year":"2018","unstructured":"Njoku, A. et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis. Europace 20, 33\u201342 (2018).","journal-title":"Europace"},{"key":"3266_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.CIR.89.2.724","volume":"89","author":"SM Vaziri","year":"1994","unstructured":"Vaziri, S. M., Larson, M. G., Benjamin, E. J. & Levy, D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 89, 724\u2013730 (1994).","journal-title":"Circulation"},{"key":"3266_CR8","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.004","volume":"25","author":"ST Broughton","year":"2016","unstructured":"Broughton, S. T., O\u2019Neal, W. T., Salahuddin, T. & Soliman, E. Z. The influence of left atrial enlargement on the relationship between atrial fibrillation and stroke. J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. 25, 1396\u20131402 (2016).","journal-title":"J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc."},{"key":"3266_CR9","doi-asserted-by":"crossref","unstructured":"Ogata, T. et al. Left atrial size and long-term risk of recurrent stroke after acute ischemic stroke in patients with nonvalvular atrial fibrillation. J. Am. Heart Assoc. 6 (2017).","DOI":"10.1161\/JAHA.117.006402"},{"key":"3266_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.08.025","volume":"27","author":"K Dakay","year":"2018","unstructured":"Dakay, K. et al. Left atrial enlargement and anticoagulation status in patients with acute ischemic stroke and atrial fibrillation. J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. 27, 192\u2013197 (2018).","journal-title":"J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc."},{"key":"3266_CR11","doi-asserted-by":"publisher","first-page":"31042","DOI":"10.1038\/srep31042","volume":"6","author":"Y Hamatani","year":"2016","unstructured":"Hamatani, Y. et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci. Rep. 6, 31042 (2016).","journal-title":"Sci. Rep."},{"key":"3266_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. Off. Publ. Am. Soc. Echocardiogr. 28, 1-39.e14 (2015).","journal-title":"J. Am. Soc. Echocardiogr. Off. Publ. Am. Soc. Echocardiogr."},{"key":"3266_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000508211","volume":"49","author":"BYQ Tan","year":"2020","unstructured":"Tan, B. Y. Q. et al. Left Atrial volume index predicts new-onset atrial fibrillation and stroke recurrence in patients with embolic stroke of undetermined source. Cerebrovasc. Dis. 49, 285\u2013291 (2020).","journal-title":"Cerebrovasc. Dis."},{"key":"3266_CR14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4070\/kcj.2017.0146","volume":"47","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. A prospective survey of atrial fibrillation management for real-world guideline adherence: Comparison study of drugs for symptom control and complication prevention of atrial fibrillation (CODE-AF) registry. Korean Circ. J. 47, 877\u2013887 (2017).","journal-title":"Korean Circ. J."},{"key":"3266_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks, K. A. et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A report of the American College of Cardiology\/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J. Am. Coll. Cardiol. 66, 403\u2013469 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3266_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S. & Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692\u2013694 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"3266_CR17","doi-asserted-by":"publisher","first-page":"53714","DOI":"10.18632\/oncotarget.16342","volume":"8","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget 8, 53714 (2017).","journal-title":"Oncotarget"},{"key":"3266_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jjcc.2009.10.008","volume":"55","author":"T Katayama","year":"2010","unstructured":"Katayama, T., Fujiwara, N. & Tsuruya, Y. Factors contributing to left atrial enlargement in adults with normal left ventricular systolic function. J. Cardiol. 55, 196\u2013204 (2010).","journal-title":"J. Cardiol."},{"key":"3266_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.amjcard.2017.04.013","volume":"120","author":"G Huang","year":"2017","unstructured":"Huang, G., Parikh, P. B., Malhotra, A., Gruberg, L. & Kort, S. Relation of body mass index and gender to left atrial size and atrial fibrillation. Am. J. Cardiol. 120, 218\u2013222 (2017).","journal-title":"Am. J. Cardiol."},{"key":"3266_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.amjcard.2013.01.305","volume":"111","author":"W AlJaroudi","year":"2013","unstructured":"AlJaroudi, W. et al. Effect of age, gender, and left ventricular diastolic function on left atrial volume index in adults without known cardiovascular disease or risk factors. Am. J. Cardiol. 111, 1517\u20131522 (2013).","journal-title":"Am. J. Cardiol."},{"key":"3266_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/hy0302.105683","volume":"39","author":"E Gerdts","year":"2002","unstructured":"Gerdts, E. et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension (Dallas Tex.) 39, 739\u2013743 (2002).","journal-title":"Hypertension (Dallas Tex.)"},{"key":"3266_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/01.hjh.0000163158.14493.23","volume":"23","author":"C Cuspidi","year":"2005","unstructured":"Cuspidi, C. et al. Prevalence and correlates of left atrial enlargement in essential hypertension: Role of ventricular geometry and the metabolic syndrome: The evaluation of target organ damage in hypertension study. J. Hypertens. 23, 875\u2013882 (2005).","journal-title":"J. Hypertens."},{"key":"3266_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1160\/TH15-12-0923","volume":"116","author":"TF Overvad","year":"2016","unstructured":"Overvad, T. F., Nielsen, P. B., Larsen, T. B. & S\u00f8gaard, P. Left atrial size and risk of stroke in patients in sinus rhythm. A systematic review. Thromb. Haemost. 116, 206\u2013219 (2016).","journal-title":"Thromb. Haemost."},{"key":"3266_CR24","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1161\/STROKEAHA.115.008711","volume":"46","author":"S Yaghi","year":"2015","unstructured":"Yaghi, S. et al. Left atrial enlargement and stroke recurrence: the Northern Manhattan stroke study. Stroke 46, 1488\u20131493 (2015).","journal-title":"Stroke"},{"key":"3266_CR25","doi-asserted-by":"publisher","first-page":"e006841","DOI":"10.1161\/CIRCEP.118.006841","volume":"12","author":"LV Boersma","year":"2019","unstructured":"Boersma, L. V. et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology: Final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage. Circ. Arrhythmia Electrophysiol. 12, e006841 (2019).","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"3266_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/icvts\/ivz156","volume":"29","author":"C Toale","year":"2019","unstructured":"Toale, C., Fitzmaurice, G. J., Eaton, D., Lyne, J. & Redmond, K. C. Outcomes of left atrial appendage occlusion using the AtriClip device: A systematic review. Interact. Cardiovasc. Thorac. Surg. 29, 655\u2013662 (2019).","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"3266_CR27","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/eurheartj\/ehaa169","volume":"41","author":"D Hildick-Smith","year":"2020","unstructured":"Hildick-Smith, D. et al. Left atrial appendage occlusion with the Amplatzer\u2122 Amulet\u2122 device: Full results of the prospective global observational study. Eur. Heart J. 41, 2894\u20132901 (2020).","journal-title":"Eur. Heart J."},{"key":"3266_CR28","doi-asserted-by":"publisher","first-page":"e0243866","DOI":"10.1371\/journal.pone.0243866","volume":"15","author":"VC Wu","year":"2020","unstructured":"Wu, V. C. et al. Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement. PLoS ONE 15, e0243866 (2020).","journal-title":"PLoS ONE"},{"key":"3266_CR29","doi-asserted-by":"crossref","unstructured":"Patti, G., Di Gioia, G., Cavallari, I. & Nenna, A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials. Diabetes Metab. Res. Rev. 33 (2017).","DOI":"10.1002\/dmrr.2876"},{"key":"3266_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/HYPERTENSIONAHA.119.13138","volume":"74","author":"S Park","year":"2019","unstructured":"Park, S. et al. Edoxaban versus warfarin stratified by average blood pressure in 19,679 patients with atrial fibrillation and a history of hypertension in the ENGAGE AF-TIMI 48 trial. Hypertension (Dallas Tex.) 74, 597\u2013605 (2019).","journal-title":"Hypertension (Dallas Tex.)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03266-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03266-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03266-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:09:48Z","timestamp":1670090988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03266-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3266"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03266-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23808"}}